



CLAIMS

1. A compound of the formula (I)



(wherein the asterisks denote chiral centers), its stereoisomers and salts thereof.

- 5 2. Compound according to claim 1 having formula (Ia):



its stereoisomers and salts thereof.

3. Compound according to claim 1, wherein said compound is selected from:


- 10
- (S)-1-((2S,4R)-1-(4-(benzyloxy)-3,5-difluorobenzoyl)-4-fluoropyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile
 - (R)-1-((2S,4R)-1-(4-(benzyloxy)-3,5-difluorobenzoyl)-4-fluoropyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile (S)-1-((2R,4R)-1-(4-(benzyloxy)-3,5-difluorobenzoyl)-4-fluoropyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile
 - (R)-1-((2R,4R)-1-(4-(benzyloxy)-3,5-difluorobenzoyl)-4-fluoropyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile
- 15

- (S)-1-((2S,4S)-1-(4-(benzyloxy)-3,5-difluorobenzoyl)-4-fluoropyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile
- (R)-1-((2S,4S)-1-(4-(benzyloxy)-3,5-difluorobenzoyl)-4-fluoropyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile
- 5 • (S)-1-((2R,4S)-1-(4-(benzyloxy)-3,5-difluorobenzoyl)-4-fluoropyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile
- (R)-1-((2R,4S)-1-(4-(benzyloxy)-3,5-difluorobenzoyl)-4-fluoropyrrolidine-2-carbonyl)pyrrolidine-2-carbonitrile,


and salts thereof.

- 10 4. A process for the preparation of a compound of formula (I) as defined in any of claims 1 to 3, which comprises

a) reacting a compound of formula (IX):




with a compound of formula (XI):




15

to yield a compound of formula (XII):

50




b) hydrolising the compound of formula (XII) to yield the compound of formula (XIV):




and

- 5 c) subjecting the compound of formula (XIV) to conditions capable of transforming a carboxamide group into a nitrile group to yield the compound of formula (I):
- wherein steps b) and c) may be performed separately or in a one pot reaction.
5. A process for the preparation of a compound of formula (I) as defined in any of claims 1 to 3 its stereoisomers and salts thereof, which comprises reacting a
- 10 compound of formula (IX):

51



with a compound of formula (IV):



5

6. A pharmaceutical composition comprising at least one compound of formula (I) as defined in any of claims 1 to 3, its stereoisomers and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier, adjuvant or vehicle.
7. A compound of formula (I) as defined in any of claims 1 to 3 for use as a medicament.
- 10 8. A compound of formula (I) as defined in any of claims 1 to 3 for use in the treatment and/or prophylaxis of a cognitive disorder.
9. A compound for use as defined in claim 8 wherein the cognitive disorder is a cognitive disorder associated with a disease selected from the group consisting of schizophrenia, major depressive disorder, bipolar affective disorder, REM sleep behavior disorder, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Lewy body disease, multiple systems atrophy, progressive supranuclear palsy, cortico-basal degeneration or amyotrophic lateral sclerosis.
- 15 10. A method for the treatment or prophylaxis of cognitive disorders in a mammal wherein a therapeutic amount of a compound as defined in any of claim 1 to 3 is administered to a patient in need of said treatment.
- 20 11. A method as defined in claim 10 wherein the cognitive disorder is a cognitive disorder associated with a disease selected from the group consisting of schizophrenia, major depressive disorder, bipolar affective disorder, REM sleep

behavior disorder, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Lewy body disease, multiple systems atrophy, progressive supranuclear palsy, cortico-basal degeneration or amyotrophic lateral sclerosis.

12. A method according to any one of claims 10 to 11 wherein the therapeutic amount
5 of a compound is administered orally to the patient.
13. Use of a compound of formula (I) as defined in any of claims 1 to 3 for the manufacture of a medicament.
14. Use of a compound of formula (I) as defined in any of claims 1 to 3 for the
10 manufacture of a medicament for the treatment and/or prophylaxis of a cognitive disorder.
15. Use as defined in claim 14 wherein the cognitive disorder is a cognitive disorder associated with a disease selected from the group consisting of schizophrenia, major depressive disorder, bipolar affective disorder, REM sleep behavior disorder, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Lewy body
15 disease, multiple systems atrophy, progressive supranuclear palsy, cortico-basal degeneration or amyotrophic lateral sclerosis.